IRIS
ZUCALI, PAOLO ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.378
AS - Asia 5.238
EU - Europa 2.113
SA - Sud America 1.329
Continente sconosciuto - Info sul continente non disponibili 292
AF - Africa 276
OC - Oceania 8
AN - Antartide 1
Totale 17.635
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.110
SG - Singapore 3.150
BR - Brasile 1.081
CN - Cina 793
IT - Italia 732
VN - Vietnam 629
FI - Finlandia 329
IE - Irlanda 290
NG - Nigeria 191
CA - Canada 158
DE - Germania 153
HK - Hong Kong 146
FR - Francia 130
GB - Regno Unito 115
AR - Argentina 98
SE - Svezia 93
IN - India 85
TR - Turchia 83
NL - Olanda 75
BD - Bangladesh 61
EC - Ecuador 49
IQ - Iraq 47
MX - Messico 47
ID - Indonesia 35
IL - Israele 33
CO - Colombia 31
RU - Federazione Russa 29
PL - Polonia 28
JP - Giappone 24
ES - Italia 23
UA - Ucraina 23
PK - Pakistan 22
ZA - Sudafrica 21
CL - Cile 19
MA - Marocco 17
PY - Paraguay 16
MY - Malesia 15
VE - Venezuela 15
BE - Belgio 14
EG - Egitto 14
EU - Europa 13
IR - Iran 12
UZ - Uzbekistan 12
AE - Emirati Arabi Uniti 11
TW - Taiwan 11
NP - Nepal 10
PT - Portogallo 10
DZ - Algeria 9
HN - Honduras 9
JO - Giordania 9
UY - Uruguay 9
DO - Repubblica Dominicana 8
JM - Giamaica 8
LT - Lituania 8
SA - Arabia Saudita 8
A2 - ???statistics.table.value.countryCode.A2??? 7
AU - Australia 7
CH - Svizzera 7
PE - Perù 7
PH - Filippine 7
TT - Trinidad e Tobago 7
AL - Albania 6
CR - Costa Rica 6
CZ - Repubblica Ceca 6
KE - Kenya 6
SV - El Salvador 6
TN - Tunisia 6
AT - Austria 5
ET - Etiopia 5
LB - Libano 5
NI - Nicaragua 5
AZ - Azerbaigian 4
GR - Grecia 4
GT - Guatemala 4
LV - Lettonia 4
OM - Oman 4
SN - Senegal 4
BA - Bosnia-Erzegovina 3
DK - Danimarca 3
GE - Georgia 3
HU - Ungheria 3
PR - Porto Rico 3
RO - Romania 3
AM - Armenia 2
BG - Bulgaria 2
BH - Bahrain 2
BO - Bolivia 2
BY - Bielorussia 2
HR - Croazia 2
KZ - Kazakistan 2
MK - Macedonia 2
NO - Norvegia 2
PS - Palestinian Territory 2
QA - Qatar 2
RS - Serbia 2
VC - Saint Vincent e Grenadine 2
AF - Afghanistan, Repubblica islamica di 1
AG - Antigua e Barbuda 1
AQ - Antartide 1
AW - Aruba 1
Totale 17.341
Salva come PNG Salva come JPEG
Città #
Singapore 1.372
Wilmington 924
Ashburn 596
Chandler 558
The Dalles 441
San Mateo 379
Dallas 357
San Jose 357
Shanghai 343
Milan 321
Helsinki 320
Dublin 290
Council Bluffs 269
Ann Arbor 262
Ho Chi Minh City 235
New York 231
Princeton 201
Benin City 190
Lawrence 187
Beijing 186
Leawood 179
Santa Clara 160
Hanoi 147
Hong Kong 135
Los Angeles 126
Woodbridge 121
São Paulo 106
Paris 105
Rome 102
Fairfield 101
Boardman 99
Phoenix 81
Amsterdam 70
Toronto 67
Kocaeli 52
London 51
Buffalo 48
Seattle 44
Chicago 35
Rio de Janeiro 32
Da Nang 31
Figino 31
Cincinnati 28
Naples 28
San Diego 28
Brooklyn 25
Curitiba 24
Houston 24
Redwood City 24
Montreal 22
Norwalk 22
Warsaw 22
Baghdad 21
Belo Horizonte 21
Brasília 21
Charlotte 21
Miami 21
The Bronx 21
Columbus 20
Chennai 19
Haiphong 19
Porto Alegre 18
Mexico City 17
Atlanta 16
Boston 16
Louisville 16
Orem 16
Philadelphia 16
Stockholm 16
Guayaquil 15
Brussels 14
Denver 14
Munich 14
Thái Bình 14
Turin 14
Frankfurt am Main 13
Manchester 13
Monmouth Junction 13
Pittsburgh 13
Quito 13
Redmond 13
Salvador 13
Tokyo 13
Fortaleza 12
Queens 12
Bologna 11
Buenos Aires 11
Campinas 11
Carapicuíba 11
Istanbul 11
Las Vegas 11
Ottawa 11
Pune 11
Richmond 11
Biên Hòa 10
Can Tho 10
Dhaka 10
Tashkent 10
Ankara 9
Asunción 9
Totale 10.874
Salva come PNG Salva come JPEG
Nome #
Activity of a specific inhibitor, gefitinib (Iressa, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer 179
Gene methylation in pleural mesothelioma : Correlations with clinico-pathological features and patient’s follow-up 139
Phase II study of avelumab plus intermittent axitinib in previously untreated patients with metastatic renal cell carcinoma (Tide-A study) 136
721P Ipilimumab and nivolumab compassionate use program in metastatic renal cell carcinoma patients with intermediate or poor IMDC risk score: The large multicenter Italian study 136
Carbon-11-methionine PET-CT as an imaging biomarker in brain gliomas eligible for surgery 132
Addition of temozolomide to radiotherapy for treatment of newly diagnosed anaplastic gliomas 127
VINORELBINE (V) IN PEMETREXED-PRETREATED PATIENTS (PTS) WITH MALIGNANT PLEURAL MESOTHELIOMA (MPM) 126
Treatment of malignant pleural mesothelioma: current status and future directions 123
Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with solid tumors 122
Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer 121
A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis 120
Prognostic value of molecular and imaging biomarkers in patients with supratentorial glioma 119
Short schedule of cisplatin and vinorelbine: A dose-finding study in non-small-cell lung cancer 115
Checkpoint inhibitors as treatment for malignant gliomas: "A long way to the top" 109
PHASE II STUDY OF THE COMBINATION OF BEVACIZUMAB PLUS PEMETREXED AND CARBOPLATIN AS FIRST-LINE THERAPY IN PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA (MPM) 109
Advances in the biology of malignant pleural mesothelioma 109
Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors 108
Computed tomography (CT)-derived radiomic features differentiate prevascular mediastinum masses as thymic neoplasms versus lymphomas 107
2-¹⁸fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial 107
Minidose warfarin prophylaxis for catheter-associated thrombosis in cancer patients: Can it be safely associated with fluorouracil-based chemotherapy? 106
Neutrophil to Lymphocyte Ratio (NLR) as predictive factor in patients with metastatic soft tissue sarcoma (STS) treated with trabectedin (T). 106
Precision medicine in Salivary Gland Carcinoma: Insights from breast and prostate cancer 105
Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors 104
[Combination of 5-Fluorouracil and folinic acid--is it still the standard therapy for advanced colorectal carcinoma?] 104
Reproducibility of the WHO classification of thymomas: practical implications 103
Digital analysis of intratumoural heterogeneity reveals higher leucocytic infiltrate in VETC (Vessels Encapsulating Tumour Clusters) areas 103
Association of Polymorphisms in AKT1 and EGFR with Clinical Outcome and Toxicity in Non-Small Cell Lung Cancer Patients Treated with Gefitinib 101
Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors 101
The Rare Entity of Basaloid Thymic Carcinoma: A Multicentric Retrospective Analysis from the Italian Collaborative Group for ThYmic MalignanciEs (TYME) 99
A phase II study of the combination of gemcitabine and imatinib mesylate in pemetrexed-pretreated patients with malignant pleural mesothelioma 99
Insulin-Like Growth Factor-1 Receptor and Phosphorylated AKT-Serine 473 Expression in 132 Resected Thymomas and Thymic Carcinomas 99
Prophylaxis of central venous catheter-related thrombosis with minidose warfarin: Analysis of its use in 427 cancer patients 97
Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [F-18]fluorodeoxyglucose 97
Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors 96
Irinotecan and raltitrexed: an active combination in advanced colorectal cancer 96
Phase II Study of Asparagine-Glycine-Arginine-Human Tumor Necrosis Factor alpha, a Selective Vascular Targeting Agent, in Previously Treated Patients With Malignant Pleural Mesothelioma 96
Assessment of tumor response in malignant pleural mesothelioma 95
Activity and safety of trabectedin in patients with sarcomatoid / biphasic malignant pleural mesothelioma (MPM) 94
Malignant mesothelioma-associated inflammatory microenvironment promotes tumor progression via GPNMB 93
Targeted therapy for thymic epithelial tumors: a new horizon ? Review of the literature and two cases reports 91
Prognostic and predictive role of [F-18]fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up-front pemetrexed-based chemotherapy 90
A phase 1 dose-escalation study of the oral histone deacetylase inhibitor abexinostat in combination with standard hypofractionated radiotherapy in advanced solid tumors 90
Second-line chemotherapy in malignant pleural mesothelioma: Results of a retrospective multicenter survey 89
Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors 89
Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy 89
Changes in shedding of soluble tumor necrosis factor receptors (sR1/R2) and in dynamic MRI as early predictors of outcome with NGR-hTNF 89
Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1 in patients with hepatocellular carcinoma 89
IMPACT OF SOLUBLE TUMOR NECROSIS FACTOR-RECEPTORS (STNF-RS) SHEDDING ON OUTCOME IN PATIENTS TREATED WITH NGR-HTNF 88
Randomized phase II study on gemcitabine with or without ramucirumab as second-line treatment for advanced malignant pleural mesothelioma (MPM): Results of Italian Rames Study 87
Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumors 87
Management of germ cell tumors during the outbreak of the novel coronavirus disease‐19 pandemic: a survey of international expertise centers 87
Anti-angiogenic therapies for malignant pleural mesothelioma 87
New tricks for old biomarkers: thymidylate synthase expression as a predictor of pemetrexed activity in malignant mesothelioma 86
Response to Sunitinib in an Adult Patient With Rhabdoid Renal Cell Carcinoma 86
Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma 86
"One marker does not fit all": additional translational and validation studies are needed to identify faithful predictors of pemetrexed activity in mesothelioma 85
Baseline Radiomic CT Features Differentiate Mediastinal Masses As Thymic Neoplasms Or Lymphomas 84
Expression and mutational status of c-kit in thymic epithelial tumors 84
Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma 84
Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. 84
THE ROLE OF THYMIDTYLATE SYNTHASE (TS) AND EXCISION REPAIR CROSS-COMPLEMENTING GROUP 1 (ERCC1) IMMUNOHISTOCHEMICAL EXPRESSION IN MALIGNANT PLEURAL MESOTHELIOMA (MPM) PATIENTS TREATED WITH PEMETREXED AND CARBOPLATIN 84
Imaging biomarkers in primary brain tumours 84
Current Perspectives on Immunotherapy in the Peri-Operative Setting of Muscle-Infiltrating Bladder Cancer. 84
A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors 83
Role of chemotherapy in combination with hormonal therapy in first-line treatment of metastatic hormone-sensitive prostate cancer 83
Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study 83
RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma 83
New target therapies in prostate cancer: from radioligand therapy, to PARP-inhibitors and immunotherapy 82
The "old drug" dacarbazine as a second/third line chemotherapy in advanced soft tissue sarcomas 82
Thymidylate Synthase and Excision Repair Cross-Complementing Group-1 as Predictors of Responsiveness in Mesothelioma Patients Treated with Pemetrexed/Carboplatin 82
Survival Outcomes in Malignant Pleural Mesothelioma Patients Fit for Surgery According to Type of Procedure and Completeness of Resection 82
Antiproliferative effects of novel aliphatic acetogenin analogs against aggressive solid tumor cell lines 82
A specific inhibitor of lactate dehydrogenase overcame the resistance toward gemcitabine in hypoxic mesothelioma cells, and modulated the expression of the human equilibrative transporter-1 82
SNPs in PI3K-PTEN-mTOR and brain metastases in NSCLC--letter 82
Advances in drug treatments for mesothelioma 81
Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma 81
Minidose warfarin is associated with a high incidence of International Normalized Ratio elevation during chemotherapy with FOLFOX regimen 81
Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin 81
Vessels encapsulating tumour clusters (VETC) in renal cell carcinoma (RCC). prognostic role and predictive value to tyrosine kinase inhibitors (TKI) therapy. A Bayesian retrospective clinico-pathological study 81
Intratumoral Switch of Molecular Phenotype and Overall Survival in Muscle Invasive Bladder Cancer 80
Comorbidity, postoperative morbidity and survival in patients undergoing radical surgery for malignant pleural mesothelioma 80
The Role of Pemetrexed in the Pharmacotherapy of Malignant Pleural Mesothelioma 80
Baseline and early change of systemic inflammation index (bSII and ΔSII) as prognostic factors in metastatic renal cell carcinoma (mRCC) patients treated with Nivolumab: Final results of the Meet-URO 15 (I-BIO-REC) study 80
Emerging Radiopharmaceuticals in Pet Imaging for Mesothelioma: A Review of [18F]FDG Alternatives 79
Phase II study of Pemetrexed and Carboplatin plus Bevacizumab as first-line therapy in malignant pleural mesothelioma 79
Incidence and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with metastatic castration-resistant prostate cancer 79
NUT rearrangement is uncommon in human thymic epithelial tumors 79
MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients 78
SAKK 17/16 - Lurbinectedin as second or third line palliative chemotherapy in malignant pleural mesothelioma (MPM): A multi-center, single-arm phase II trial 78
Mutational Profile of Malignant Pleural Mesothelioma (MPM) in the Phase II RAMES Study 78
The neural phenotype in invasive urothelial carcinoma patients: Alternative score detection and prognostic implication 78
Baseline and early change of neutrophil to lymphocyte ratio (bNLR and ΔNLR) as prognostic factors in metastatic renal cell carcinoma (mRCC) treated with Nivolumab: Final results of the Meet-URO 15 (I-BIO-REC) study 78
Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study 78
Epithelioid Pleural Mesothelioma Is Characterized by Tertiary Lymphoid Structures in Long Survivors: Results from the MATCH Study 77
Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial 77
Malignant pleural mesothelioma (MPM) evaluation with C-11-methionine PET/CT before and after talc pleurodesis 77
Phase I, pharmacokinetics, pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors 77
EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations 76
Biology and management of malignant pleural mesothelioma 76
Outcome of EGFR inhibitors treatment in advanced NSCLC patients, not enrolled in clinical trials 76
Totale 9.372
Salva come PNG Salva come JPEG
Categoria #
all - tutte 114.671
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 114.671
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022936 0 0 28 185 15 6 37 128 100 112 290 35
2022/20231.975 408 65 217 169 131 127 6 127 322 224 161 18
2023/20241.345 117 142 244 40 30 183 84 78 27 28 140 232
2024/20252.264 20 70 23 38 68 270 112 187 316 546 292 322
2025/20267.342 917 624 529 921 240 312 1.632 361 375 373 315 743
2026/20271.724 812 540 372 0 0 0 0 0 0 0 0 0
Totale 17.635